Beta Drugs (NSE:BETA) ROE % Adjusted to Book Value: 3.01% (As of Mar. 2026)

Beta Drugs NSE:BETA +0.01% 86 ROE % Adjusted to Book Value is 3.01% as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 86/100 and a GF Value™ of ₹1,966.81 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beta Drugs's ROE % for the quarter that ended in Mar. 2026 was 14.79%. Beta Drugs's PB Ratio for the quarter that ended in Mar. 2026 was 4.92. Beta Drugs's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.01%.

Beta Drugs ROE % Adjusted to Book Value Related Terms

Beta Drugs ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Beta Drugs's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs ROE % Adjusted to Book Value Chart

Beta Drugs Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

5.24

5.83

3.45

2.45

3.81

Beta Drugs Quarterly Data
	Mar17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Dec24	Mar25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	1.88	0.00	0.00	3.01

NSE:BETA vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Drugs ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Beta Drugs's ROE % Adjusted to Book Value falls into.

Save Embed

86GF Score

Beta Drugs Ltd NSE:BETA

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Beta Drugs ROE % Adjusted to Book Value Calculation

Beta Drugs's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	18.78%	/	4.93
	=	3.81%

Beta Drugs's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	14.79%	/	4.92
	=	3.01%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 3.01% mean?

Beta Drugs (NSE:BETA) has a ROE % Adjusted to Book Value of 3.01% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beta Drugs and its competitors.

Is Beta Drugs' ROE % Adjusted to Book Value too high?

Beta Drugs' current ROE % Adjusted to Book Value is 3.01%. Overall, Beta Drugs has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Beta Drugs' ROE % Adjusted to Book Value compare to ZTS and UTHR?

Beta Drugs' ROE % Adjusted to Book Value of 3.01% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?

A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beta Drugs and its competitors. Beta Drugs's current ROE % Adjusted to Book Value is 3.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Beta Drugs stock overvalued right now?

Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,966.81, compared to a current price of ₹2,185.00 — trading 11.1% above its estimated fair value. The current ROE % Adjusted to Book Value is 3.01%. Beta Drugs' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current ROE % Adjusted to Book Value is 3.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,185.00 is trading 11.1% above its estimated GF Value™ of ₹1,966.81. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

ROE % Adjusted to Book Value: 3.01%
GF Value™: ₹1,966.81 vs. price of ₹2,185.00 (11.1% above fair value)
GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:532612 BOM:524669 BOM:543329 NSE:SAKAR BOM:532305 BOM:539997 BOM:526953 BOM:524735 BOM:590006 BOM:541540 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114

Website https://www.betadrugslimited.com

Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.

86GF Score

Get the complete analysis for NSE:BETA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,185.00

Price

₹1,966.81

GF Value

View NSE:BETA Analysis

See ROE % Adjusted to Book Value data for all stocks →